HYDROMORPHONE HYDROCHLORIDE

Growth

hydromorphone hydrochloride

NDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
45/100
Clinical Trials
4

Mechanism of Action

mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of hydromorphone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and…

Clinical Trials (4)

NCT01205126Phase 3Completed

An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain

Started Dec 2009
260 enrolled
Pain
NCT00803283Phase 3Terminated

A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain

Started Nov 2008
2 enrolled
Cancer Pain
NCT01006356Phase 4Completed

An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer

Started Oct 2008
141 enrolled
CancerPain
NCT00980798Phase 3Completed

Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee

Started Oct 2007
288 enrolled
PainOsteoarthritis, HipOsteoarthritis, Knee